UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2021~~March 31, 2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number: 001-31719

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)


Delaware		13-4204626
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 Oceangate, Suite 100
Long Beach,	California	90802
(Address of principal executive offices)		(Zip Code)

(562) 435-3666

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 Par Value	MOH	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☒ Accelerated Filer ☐ Non-Accelerated Filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the issuer’s Common Stock, $0.001 par value, outstanding as of ~~October~~April 22, ~~2021,~~2022, was approximately ~~58,400,000.~~58,700,000.

Table of Contents

MOLINA HEALTHCARE, INC. FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER 30, 2021~~MARCH 31, 2022

TABLE OF CONTENTS


ITEM NUMBER	ITEM NUMBER		Page	ITEM NUMBER		Page

PART I	PART I			PART I

1.	1.	Financial Statements	3	1.	Financial Statements	3

2.	2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21	2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

3.	3.	Quantitative and Qualitative Disclosures About Market Risk	36	3.	Quantitative and Qualitative Disclosures About Market Risk	31

4.	4.	Controls and Procedures	36	4.	Controls and Procedures	31

PART II	PART II			PART II

1.	1.	Legal Proceedings	36	1.	Legal Proceedings	31

1A.	1A.	Risk Factors	36	1A.	Risk Factors	31

2.	2.	Unregistered Sales of Equity Securities and Use of Proceeds	37	2.	Unregistered Sales of Equity Securities and Use of Proceeds	32

3.	3.	Defaults Upon Senior Securities	Not Applicable.	3.	Defaults Upon Senior Securities	Not Applicable.

4.	4.	Mine Safety Disclosures	Not Applicable.	4.	Mine Safety Disclosures	Not Applicable.

5.	5.	Other Information	Not Applicable.	5.	Other Information	Not Applicable.

6.	6.	Exhibits	38	6.	Exhibits	33

		Signatures	39		Signatures	34

Table of Contents

CONSOLIDATED STATEMENTS OF INCOME


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended March 31,
		2021		2020		2021		2020			2022		2021

		(In millions, except per-share amounts) (Unaudited)									(In millions, except per-share amounts) (Unaudited)
Revenue:	Revenue:									Revenue:
Premium revenue	Premium revenue	$	6,800	$	4,768	$	19,689	$	13,444	Premium revenue	$	7,531	$	6,306
Premium tax revenue	Premium tax revenue	204		170		576		477		Premium tax revenue	208		187
Health insurer fees reimbursed		—		69		—		206

Investment income	Investment income	20		10		39		48		Investment income	11		9
Other revenue	Other revenue	16		4		58		13		Other revenue	20		20
Total revenue	Total revenue	7,040		5,021		20,362		14,188		Total revenue	7,770		6,522
Operating expenses:	Operating expenses:									Operating expenses:
Medical care costs	Medical care costs	6,049		4,098		17,342		11,412		Medical care costs	6,563		5,474
General and administrative expenses	General and administrative expenses	532		368		1,489		1,030		General and administrative expenses	571		473
Premium tax expenses	Premium tax expenses	204		170		576		477		Premium tax expenses	208		187
Health insurer fees		—		70		—		209

Depreciation and amortization	Depreciation and amortization	32		23		96		64		Depreciation and amortization	40		33
Other	Other	2		3		30		9		Other	16		20
Total operating expenses	Total operating expenses	6,819		4,732		19,533		13,201		Total operating expenses	7,398		6,187
Operating income	Operating income	221		289		829		987		Operating income	372		335
Other expenses, net:	Other expenses, net:									Other expenses, net:
Interest expense	Interest expense	30		27		90		72		Interest expense	28		30
Other expense, net		—		—		—		5

Total other expenses, net	Total other expenses, net	30		27		90		77		Total other expenses, net	28		30
Income before income tax expense	Income before income tax expense	191		262		739		910		Income before income tax expense	344		305
Income tax expense	Income tax expense	48		77		183		271		Income tax expense	86		77
Net income	Net income	$	143	$	185	$	556	$	639	Net income	$	258	$	228

Net income per share - Basic	Net income per share - Basic	$	2.49	$	3.14	$	9.63	$	10.80	Net income per share - Basic	$	4.45	$	3.95
Net income per share - Diluted	Net income per share - Diluted	$	2.46	$	3.10	$	9.51	$	10.65	Net income per share - Diluted	$	4.39	$	3.89

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended March 31,
		2021		2020		2021		2020			2022		2021

		(In millions) (Unaudited)									(In millions) (Unaudited)
Net income	Net income	$	143	$	185	$	556	$	639	Net income	$	258	$	228
Other comprehensive loss income:
Unrealized investment (loss) income		(13)		6		(27)		43
Other comprehensive loss:										Other comprehensive loss:
Unrealized investment loss										Unrealized investment loss	(100)		(15)
Less: effect of income taxes	Less: effect of income taxes	(4)		1		(7)		10		Less: effect of income taxes	(24)		(4)
Other comprehensive (loss) income, net of tax		(9)		5		(20)		33
Other comprehensive loss, net of tax										Other comprehensive loss, net of tax	(76)		(11)
Comprehensive income	Comprehensive income	$	134	$	190	$	536	$	672	Comprehensive income	$	182	$	217

See accompanying notes.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3

Table of Contents

CONSOLIDATED BALANCE SHEETS


		September 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021

		(Dollars in millions, except per-share amounts)					(Dollars in millions, except per-share amounts)
		(Unaudited)					(Unaudited)
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	4,357	$	4,154	Cash and cash equivalents	$	4,804	$	4,438
Investments	Investments	2,900		1,875		Investments	2,988		3,202
Receivables	Receivables	1,912		1,672		Receivables	2,156		2,177
Prepaid expenses and other current assets	Prepaid expenses and other current assets	197		175		Prepaid expenses and other current assets	198		247
Total current assets	Total current assets	9,366		7,876		Total current assets	10,146		10,064
Property, equipment, and capitalized software, net	Property, equipment, and capitalized software, net	385		391		Property, equipment, and capitalized software, net	393		396
Goodwill, and intangible assets, net	Goodwill, and intangible assets, net	915		941		Goodwill, and intangible assets, net	1,305		1,252
Restricted investments	Restricted investments	156		136		Restricted investments	221		212
Deferred income taxes	Deferred income taxes	83		69		Deferred income taxes	114		106
Other assets	Other assets	128		119		Other assets	181		179
Total assets	Total assets	$	11,033	$	9,532	Total assets	$	12,360	$	12,209

LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Medical claims and benefits payable	Medical claims and benefits payable	$	3,191	$	2,696	Medical claims and benefits payable	$	3,601	$	3,363
Amounts due government agencies	Amounts due government agencies	2,081		1,253		Amounts due government agencies	2,613		2,472
Accounts payable, accrued liabilities and other	Accounts payable, accrued liabilities and other	797		641		Accounts payable, accrued liabilities and other	809		842
Deferred revenue	Deferred revenue	1		375		Deferred revenue	18		370
Total current liabilities	Total current liabilities	6,070		4,965		Total current liabilities	7,041		7,047
Long-term debt	Long-term debt	2,130		2,127		Long-term debt	2,174		2,173
Finance lease liabilities	Finance lease liabilities	220		225		Finance lease liabilities	217		219
Other long-term liabilities	Other long-term liabilities	95		119		Other long-term liabilities	134		140
Total liabilities	Total liabilities	8,515		7,436		Total liabilities	9,566		9,579
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 58 million shares at September 30, 2021, and 59 million shares at December 31, 2020		—		—
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March 31, 2022, and 58 million shares at December 31, 2021						Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at March 31, 2022, and 58 million shares at December 31, 2021	—		—
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	—		—		Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding	—		—
Additional paid-in capital	Additional paid-in capital	205		199		Additional paid-in capital	218		236
Accumulated other comprehensive income		17		37
Accumulated other comprehensive loss						Accumulated other comprehensive loss	(81)		(5)
Retained earnings	Retained earnings	2,296		1,860		Retained earnings	2,657		2,399
Total stockholders’ equity	Total stockholders’ equity	2,518		2,096		Total stockholders’ equity	2,794		2,630
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	11,033	$	9,532	Total liabilities and stockholders’ equity	$	12,360	$	12,209

See accompanying notes.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 4

Table of Contents

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY


		Common Stock			Additional Paid-in Capital				Accumulated Other Comprehensive Income			Retained Earnings				Total				Common Stock					Additional Paid-in Capital			Accumulated Other Comprehensive Loss			Retained Earnings			Total
		Outstanding	Amount								Outstanding								Amount

		(In millions)																		(In millions)
		(Unaudited)																		(Unaudited)
Balance at December 31, 2020		59	$	—			$	199						$	37			$	1,860		$	2,096
Net income		—	—		—				—			228				228
Common stock purchases		(1)	—		(2)				—			(120)				(122)

Other comprehensive loss, net		—	—		—				(11)			—				(11)
Share-based compensation		—	—		(27)				—			—				(27)
Balance at March 31, 2021		58	—		170				26			1,968				2,164
Net income		—	—		—				—			185				185

Share-based compensation		—	—		21				—			—				21
Balance at June 30, 2021		58	—		191				26			2,153				2,370
Balance at December 31, 2021																			Balance at December 31, 2021	58			$	—		$	236		$	(5)		$	2,399		$	2,630
Net income	Net income	—	—		—				—			143				143			Net income	—			—		—			—			258			258

Other comprehensive loss, net	Other comprehensive loss, net	—	—		—				(9)			—				(9)			Other comprehensive loss, net	—			—		—			(76)			—			(76)
Share-based compensation	Share-based compensation	—	—		14				—			—				14			Share-based compensation	1			—		(18)			—			—			(18)
Balance at September 30, 2021		58	$	—	$	205			$	17		$	2,296			$	2,518
Balance at March 31, 2022																			Balance at March 31, 2022	59			$	—	$	218		$	(81)		$	2,657		$	2,794


		Common Stock			Additional Paid-in Capital				Accumulated Other Comprehensive Income (Loss)			Retained Earnings				Total				Common Stock					Additional Paid-in Capital			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total
		Outstanding	Amount								Outstanding								Amount

		(In millions)																		(In millions)
		(Unaudited)																		(Unaudited)
Balance at December 31, 2019		62	$	—			$	175						$	4			$	1,781		$	1,960
Balance at December 31, 2020																			Balance at December 31, 2020	59			$	—		$	199		$	37		$	1,860		$	2,096
Net income	Net income	—	—		—				—			178				178			Net income	—			—		—			—			228			228
Common stock purchases	Common stock purchases	(3)	—		(9)				—			(437)				(446)			Common stock purchases	(1)			—		(2)			—			(120)			(122)
Termination of warrants		—	—		(30)				—			—				(30)

Other comprehensive loss, net	Other comprehensive loss, net	—	—		—				(19)			—				(19)			Other comprehensive loss, net	—			—		—			(11)			—			(11)
Share-based compensation	Share-based compensation	—	—		4				—			—				4			Share-based compensation	—			—		(27)			—			—			(27)
Balance at March 31, 2020		59	—		140				(15)			1,522				1,647
Net income		—	—		—				—			276				276
Balance at March 31, 2021																			Balance at March 31, 2021	58			$	—	$	170		$	26		$	1,968		$	2,164

Other comprehensive income, net		—	—		—				47			—				47
Share-based compensation		—	—		26				—			—				26
Balance at June 30, 2020		59	—		166				32			1,798				1,996
Net income		—	—		—				—			185				185

Other comprehensive income, net		—	—		—				5			—				5
Share-based compensation		—	—		15				—			—				15
Balance at September 30, 2020		59	$	—	$	181			$	37		$	1,983			$	2,201

See accompanying notes.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 5

Table of Contents

CONSOLIDATED STATEMENTS OF CASH FLOWS


		Nine Months Ended September 30,					Three Months Ended March 31,
		2021		2020			2022		2021

		(In millions) (Unaudited)					(In millions) (Unaudited)
Operating activities:	Operating activities:					Operating activities:
Net income	Net income	$	556	$	639	Net income	$	258	$	228
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:					Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	Depreciation and amortization	96		64		Depreciation and amortization	40		33
Deferred income taxes	Deferred income taxes	(8)		(3)		Deferred income taxes	16		6
Share-based compensation	Share-based compensation	49		43		Share-based compensation	34		24
Loss on debt repayment		—		5

Other, net	Other, net	9		2		Other, net	(8)		12
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Receivables	Receivables	(247)		(369)		Receivables	21		(98)
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(43)		(98)		Prepaid expenses and other current assets	(32)		(15)
Medical claims and benefits payable	Medical claims and benefits payable	522		431		Medical claims and benefits payable	263		168
Amounts due government agencies	Amounts due government agencies	810		(24)		Amounts due government agencies	137		432
Accounts payable, accrued liabilities and other	Accounts payable, accrued liabilities and other	129		63		Accounts payable, accrued liabilities and other	(81)		16
Deferred revenue	Deferred revenue	(374)		(188)		Deferred revenue	(352)		(304)
Income taxes	Income taxes	23		34		Income taxes	67		66
Net cash provided by operating activities	Net cash provided by operating activities	1,522		599		Net cash provided by operating activities	363		568
Investing activities:	Investing activities:					Investing activities:
Purchases of investments	Purchases of investments	(2,018)		(670)		Purchases of investments	(403)		(388)
Proceeds from sales and maturities of investments	Proceeds from sales and maturities of investments	965		891		Proceeds from sales and maturities of investments	513		308
Purchases of property, equipment and capitalized software	Purchases of property, equipment and capitalized software	(56)		(64)		Purchases of property, equipment and capitalized software	(23)		(16)
Net cash paid in business combinations		—		(62)

Other, net	Other, net	3		3		Other, net	(13)		9
Net cash (used in) provided by investing activities		(1,106)		98
Net cash provided by (used in) investing activities						Net cash provided by (used in) investing activities	74		(87)
Financing activities:	Financing activities:					Financing activities:
Common stock purchases		(128)		(453)
Common stock withheld to settle employee tax obligations	Common stock withheld to settle employee tax obligations	(52)		(8)		Common stock withheld to settle employee tax obligations	(52)		(51)
Contingent consideration liabilities settled	Contingent consideration liabilities settled	(20)		—		Contingent consideration liabilities settled	(20)		(20)
Proceeds from senior notes offering, net of issuance costs		—		789
Repayment of term loan facility		—		(600)
Proceeds from borrowings under term loan facility		—		380
Common stock purchases						Common stock purchases	—		(128)

Other, net	Other, net	(4)		(47)		Other, net	(5)		(8)
Net cash (used in) provided by financing activities		(204)		61
Net cash used in financing activities						Net cash used in financing activities	(77)		(207)
Net increase in cash, cash equivalents, and restricted cash and cash equivalents	Net increase in cash, cash equivalents, and restricted cash and cash equivalents	212		758		Net increase in cash, cash equivalents, and restricted cash and cash equivalents	360		274
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period	Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period	4,223		2,508		Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period	4,506		4,223
Cash, cash equivalents, and restricted cash and cash equivalents at end of period	Cash, cash equivalents, and restricted cash and cash equivalents at end of period	$	4,435	$	3,266	Cash, cash equivalents, and restricted cash and cash equivalents at end of period	$	4,866	$	4,497

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 6

Table of Contents

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

~~SEPTEMBER 30, 2021~~MARCH 31, 2022

1. Organization and Basis of Presentation

Organization and Operations

Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. TheseWe currently have 4 reportable segments ~~consist~~consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. ~~For further information, refer to Note 10, “Segments.”~~Our reportable segments are consistent with how we currently manage the business and view the markets we serve.

As of ~~September 30, 2021,~~March 31, 2022, we served approximately ~~4.8~~5.1 million members eligible for government-sponsored healthcare programs, located across 1819 states.

Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (“RFPs”) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.

In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (“ABD”); and regions or service areas.

Recent Developments

~~New York Acquisition—~~California Procurement—Medicaid. In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024.

Texas Procurement—Medicaid. In March 2022, the Texas Health and Human Services Commission posted the ABD program (known in Texas as STAR+PLUS) RFP, with awards estimated to be announced in the fourth quarter of 2022, and start of operations in September 2023.

Texas Acquisition—Medicaid and Medicare. On ~~October 25, 2021,~~January 1, 2022, we closed on our acquisition of ~~substantially all of the assets of Affinity Health~~Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan ~~Inc., a Medicaid health plan in New York. The net purchase price~~(“MMP”) contracts, along with certain operating assets. See Note 4, “Business Combinations,” for ~~the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.~~

~~New York Acquisition—Medicaid.~~ On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million. The purchase price for the transaction is approximately $110 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.further information.

Nevada Procurement—Medicaid.~~On August 17, 2021, we announced that our Nevada health plan subsidiary was selected as an awardee~~ Our new contract in Clark and Washoe ~~Counties. This new contract is expected to commence~~Counties commenced on January 1, 2022, and ~~will offer~~offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. The four year contract with a possible ~~two year~~two-year extension was ratified in September 2021.

~~California Procurement—Medicaid.~~ ~~The state currently expects a final RFP to be released in February 2022.~~

~~Texas Acquisition—Medicaid and Medicare.~~ On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.

~~Ohio Procurement—Medicaid.~~ On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract is expected to begin July 1, 2022, and will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs.

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 7~~

~~Table of Contents~~

Consolidation and Interim Financial Information

The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 are not necessarily indicative of the results for the entire year ending December 31, ~~2021.~~2022.

The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, ~~2020.~~2021. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December 31, ~~2020,~~2021, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December 31, ~~2020.~~

~~Reclassifications~~

Consistent with the change in reportable segments described above, certain prior year disclosures in Note 7, “Medical Claims and Benefits Payable,” and Note 10, “Segments,” have been recast to conform to the current year presentation.

Certain immaterial amounts presented in the accompanying consolidated statement of cash flows for the nine months ended September 30, 2020, have been reclassified to conform to the current year presentation.2021.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. ~~Principal areas requiring the use~~

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 7

Table of ~~estimates include:~~

•~~The determination of medical claims and benefits payable;~~Contents

•~~Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;~~

•~~Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;~~

•~~Settlements under risk- or savings-sharing programs;~~

•~~Purchase price allocations relating to business combinations, including the determination of contingent consideration;~~

•~~The assessment of long-lived and intangible assets, and goodwill for impairment;~~

•~~The determination of reserves for potential absorption of claims unpaid by insolvent providers;~~

•~~The determination of reserves for the outcome of litigation;~~

•~~The determination of valuation allowances for deferred tax assets; and~~

•~~The determination of unrecognized tax benefits.~~

2. Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table ~~reconciles~~provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in “Restricted investments” in the accompanying consolidated balance sheets.

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 8~~

~~Table of Contents~~


		September 30,					March 31,
		2021		2020			2022		2021

		(In millions)					(In millions)
Cash and cash equivalents	Cash and cash equivalents	$	4,357	$	3,196	Cash and cash equivalents	$	4,804	$	4,431
Restricted cash and cash equivalents	Restricted cash and cash equivalents	78		70		Restricted cash and cash equivalents	62		66
Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows	Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows	$	4,435	$	3,266	Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows	$	4,866	$	4,497

Receivables

Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.


		September 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021

		(In millions)					(In millions)
Government receivables	Government receivables	$	1,331	$	969	Government receivables	$	1,589	$	1,566
Pharmacy rebate receivables	Pharmacy rebate receivables	264		178		Pharmacy rebate receivables	306		276
Health insurer fee reimbursement receivables		25		104

Other	Other	292		255		Other	261		335
Magellan Complete Care acquisition opening balance		—		166

Total	Total	$	1,912	$	1,672	Total	$	2,156	$	2,177

Premium Revenue Recognition and Amounts Due Government Agencies

Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (“PMPM”) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates.

Certain components of premium revenue are subject to accounting estimates and are described in further detail below, and in our ~~2020~~2021 Annual Report on Form 10-K, Note 2, “Significant Accounting Policies,” under “Contractual Provisions That May Adjust or Limit Revenue or Profit,” and “Quality Incentives.”

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 98

Table of Contents

Contractual Provisions That May Adjust or Limit Revenue or Profit

Many of our contracts contain provisions that may adjust or limit revenue or profit, ~~which include those provisions with significant interim period balances~~as described ~~in further detail~~ below. WeConsequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as “Amounts due government agencies,” in the accompanying consolidated balance sheets. ~~Categorized by segment, such~~

The following table sets forth amounts due government agencies, ~~included the following:~~categorized by program:


		September 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021

		(In millions)					(In millions)
Medicaid:
Medicaid program:						Medicaid program:
Minimum MLR and profit sharing	Minimum MLR and profit sharing	$	852	$	513	Minimum MLR and profit sharing	$	1,033	$	1,016
Other	Other	249		76		Other	270		263
Medicare:
Medicare program:						Medicare program:
Risk adjustment and Part D risk sharing	Risk adjustment and Part D risk sharing	87		45		Risk adjustment and Part D risk sharing	105		89
Minimum MLR and profit sharing	Minimum MLR and profit sharing	82		62		Minimum MLR and profit sharing	103		101
Other	Other	41		30		Other	31		35
Marketplace:
Marketplace program:						Marketplace program:
Risk adjustment	Risk adjustment	691		326		Risk adjustment	949		902
Minimum MLR	Minimum MLR	30		37		Minimum MLR	20		18
Other	Other	49		21		Other	102		48
Magellan Complete Care acquisition opening balance		—		143

Total amounts due government agencies	Total amounts due government agencies	$	2,081	$	1,253	Total amounts due government agencies	$	2,613	$	2,472

Medicaid Program

Minimum MLR and Retroactive Premium Adjustments. State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably ~~estimable. Our adjustment is~~estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.

Beginning in 2020, ~~through September 30, 2021,~~ various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from ~~COVID-19,~~COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized ~~retroactive~~ risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, we recognized approximately ~~$17~~$28 million ~~and $183 million, respectively,~~ related to such risk corridors, primarily in the Medicaid ~~segment.~~segment, compared to $110 million recognized in the three months ended March 31, 2021. The decrease is due to the elimination of several of the COVID-19 risk corridors.

It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.

Marketplace Program

Risk Adjustment. Under this program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of ~~September 30,~~March 31, 2022, Marketplace risk adjustment payables amounted to $949 million and related receivables amounted to $33 million, for a net payable of $916 million. As of December 31, 2021, Marketplace risk adjustment payables amounted to ~~$691~~$902 million and related receivables amounted to ~~$29~~$7 million, for a net payable of $662 million, of which $660 million related to 2021, and $2 million related primarily to 2020. As of December 31, 2020, Marketplace risk adjustment payables amounted to $326 million and related receivables amounted to $20 million, for a net payable of $306$895 million.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 109

Table of Contents

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 1015 years, or less than 1015 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and ~~the local~~ governments of ~~the states~~each state in which our health plan subsidiaries operate.

Income Taxes

The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of foreign and state taxes, and nondeductible expenses such as certain compensation and other general and administrative expenses.

The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.

Recent Accounting Pronouncements

~~Various recent~~Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (“SEC”) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

3. Net Income ~~per~~Per Share

The following table sets forth the calculation of basic and diluted net income per share:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended March 31,
		2021		2020		2021		2020			2022		2021

		(In millions, except net income per share)									(In millions, except net income per share)
Numerator:	Numerator:									Numerator:
Net income	Net income	$	143	$	185	$	556	$	639	Net income	$	258	$	228
Denominator:	Denominator:									Denominator:
Shares outstanding at the beginning of the period	Shares outstanding at the beginning of the period	57.8		58.7		58.0		61.9		Shares outstanding at the beginning of the period	57.9		58.0
Weighted-average number of shares issued:	Weighted-average number of shares issued:									Weighted-average number of shares issued:
Stock-based compensation										Stock-based compensation	0.1		0.1
Stock purchases	Stock purchases	—		—		(0.5)		(2.8)		Stock purchases	—		(0.4)
Stock-based compensation		—		—		0.3		0.1
Denominator for basic net income per share	Denominator for basic net income per share	57.8		58.7		57.8		59.2		Denominator for basic net income per share	58.0		57.7
Effect of dilutive securities: (1)	Effect of dilutive securities: (1)									Effect of dilutive securities: (1)
Stock-based compensation	Stock-based compensation	0.7		0.9		0.7		0.8		Stock-based compensation	0.7		0.9

Denominator for diluted net income per share	Denominator for diluted net income per share	58.5		59.6		58.5		60.0		Denominator for diluted net income per share	58.7		58.6

Net income per share - Basic (2)	Net income per share - Basic (2)	$	2.49	$	3.14	$	9.63	$	10.80	Net income per share - Basic (2)	$	4.45	$	3.95
Net income per share - Diluted (2)	Net income per share - Diluted (2)	$	2.46	$	3.10	$	9.51	$	10.65	Net income per share - Diluted (2)	$	4.39	$	3.89

(1) The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method.

~~(2) Source data for calculations in thousands.~~

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1110

Table of Contents

(2) Source data for calculations in thousands.

4. Business Combinations

Cigna. On ~~December 31, 2020,~~January 1, 2022, we closed on our acquisition of ~~100% of the outstanding equity interests of the Magellan Complete Care line of business of Magellan Health, Inc.,~~Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for ~~total~~ purchase consideration of approximately ~~$1,037~~$60 million. We acquired membership and a provider network with a preliminary fair value of approximately $36 million. We allocated the remaining $24 million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes.

Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for initial purchase consideration of approximately $176 million. In the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, we recorded various measurement period adjustments, including a decrease of ~~$7 million to “Receivables,” a decrease of $27~~$25 million to “Medical claims and benefits payable,” and an increase of ~~$18~~$4 million to “Amounts due government agencies.” In the aggregate, we recorded a net increase of $9$11 million to goodwill for these measurement period adjustments and various purchase price adjustments.

~~Refer to Note 10, “Segments” for further information regarding the allocation of goodwill and intangible assets, net, by reportable segment.~~

5. Fair Value Measurements

We ~~generally~~ consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our ~~2020~~2021 Annual Report on Form 10-K, Note 5, “Fair Value Measurements.”

~~Our financial instruments measured at fair value on a recurring basis at September 30, 2021, were as follows:~~

Observable Inputs Directly or Indirectly Observable Inputs Unobservable Inputs
Total (Level 1) (Level 2) (Level 3)
(In millions)
Corporate debt securities $ 1,705 $ — $ 1,705 $ —
Mortgage-backed securities 610 — 610 —
U.S. Treasury notes 235 — 235 —
Asset-backed securities 224 — 224 —
Municipal securities 97 — 97 —
Other 29 — 29 —
Total assets $ 2,900 $ — $ 2,900 $ —
Contingent consideration liabilities $ 26 $ — $ — $ 26
Total liabilities $ 26 $ — $ — $ 26

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 12~~

~~Table of Contents~~

~~Our financial instruments measured at fair value on a recurring basis at December 31, 2020, were as follows:~~

Observable Inputs Directly or Indirectly Observable Inputs Unobservable Inputs
Total (Level 1) (Level 2) (Level 3)
(In millions)
Corporate debt securities $ 1,256 $ — $ 1,256 $ —
Mortgage-backed securities 392 — 392 —
U.S. Treasury notes 27 — 27 —
Asset-backed securities 132 — 132 —
Municipal securities 68 — 68 —
Total assets $ 1,875 $ — $ 1,875 $ —
Contingent consideration liabilities $ 46 $ — $ — $ 46
Total liabilities $ 46 $ — $ — $ 46

The net changes in fair value of Level 3 financial instruments are reported in “Other” operating expenses in our consolidated statements of income. In the ~~nine~~three months ended ~~September 30,~~March 31, 2022 and 2021, we recognized a loss of $3$4 million and $8 million, respectively, for the increase in the fair value of the contingent consideration liabilities described below.

~~Contingent Consideration Liabilities~~

~~As of September 30, 2021, our Level 3~~Our financial instruments ~~recorded~~measured at fair value on a recurring basis ~~included~~at March 31, 2022, were as follows:


			Observable Inputs		Directly or Indirectly Observable Inputs		Unobservable Inputs
	Total		(Level 1)		(Level 2)		(Level 3)

	(In millions)
Corporate debt securities	$	1,808	$	—	$	1,808	$	—
Mortgage-backed securities	598		—		598		—
Asset-backed securities	252		—		252		—
U.S. Treasury notes	174		—		174		—
Municipal securities	117		—		117		—



Other	39		—		39		—
Total assets	$	2,988	$	—	$	2,988	$	—

Contingent consideration liabilities	$	8	$	—	$	—	$	8
Total liabilities	$	8	$	—	$	—	$	8

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 11

Table of Contents

Our financial instruments measured at fair value on a recurring basis at December 31, 2021, were as follows:


			Observable Inputs		Directly or Indirectly Observable Inputs		Unobservable Inputs
	Total		(Level 1)		(Level 2)		(Level 3)

	(In millions)
Corporate debt securities	$	1,833	$	—	$	1,833	$	—
Mortgage-backed securities	614		—		614		—
Asset-backed securities	247		—		247		—
U.S. Treasury notes	353		—		353		—
Municipal securities	123		—		123		—


Other	32		—		32		—
Total assets	$	3,202	$	—	$	3,202	$	—

Contingent consideration liabilities	$	47	$	—	$	—	$	47
Total liabilities	$	47	$	—	$	—	$	47

Contingent Consideration Liabilities

Our Level 3 financial instruments at March 31, 2022 are comprised solely of contingent consideration liabilities of ~~$26~~$8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Such liabilities are recorded at fair value on a recurring basis. In the ~~first quarter~~three months ended March 31, 2022, the estimated fair value of ~~2021, the~~ contingent purchase consideration increased by approximately $4 million, relating to ~~2021 member enrollment~~an operating income guarantee.

In the three months ended March 31, 2022 we paid the seller $43 million, of which $23 million was ~~finalized and~~for the remaining half of the consideration due ~~or $23~~for minimum member enrollment targets and $20 million was ~~paid to~~for the ~~seller. The portion~~first payment of the ~~contingent purchase~~ consideration due for the operating income guarantee. For the amounts paid in the ~~first quarter of 2021~~three months ended March 31, 2022, $20 million has been presented ~~primarily~~ in “Financing activities” in the accompanying consolidated statements of cash flows, ~~for the nine months ended September 30, 2021,~~ with the balance reflected in “Operating activities.” ~~We expect to pay the~~The remaining balance of the liabilities is reported in “Accounts payable, accrued liabilities and other” in the accompanying consolidated balance ~~sheets, by the end of the first quarter of 2022.~~sheets.

Fair Value Measurements – Disclosure Only

The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.

September 30, 2021 December 31, 2020
Carrying
Amount Fair Value Carrying
Amount Fair Value
(In millions)
4.375% Notes $ 790 $ 835 $ 789 $ 843
5.375% Notes 698 725 697 742
3.875% Notes 642 688 641 691
Total $ 2,130 $ 2,248 $ 2,127 $ 2,276


	March 31, 2022				December 31, 2021
	Carrying Amount		Fair Value		Carrying Amount		Fair Value

	(In millions)
4.375% Notes due 2028	$	791	$	789	$	791	$	829
3.875% Notes due 2030	642		624		642		675
3.875% Notes due 2032	741		713		740		760
Total	$	2,174	$	2,126	$	2,173	$	2,264

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1312

Table of Contents

6. Investments

Available-for-Sale

We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:


		September 30, 2021									March 31, 2022
		Amortized Cost		Gross Unrealized				Estimated Fair Value			Amortized Cost		Gross Unrealized				Estimated Fair Value
				Gains		Losses							Gains		Losses

		(In millions)									(In millions)
Corporate debt securities	Corporate debt securities	$	1,688	$	19	$	2	$	1,705	Corporate debt securities	$	1,874	$	1	$	67	$	1,808
Mortgage-backed securities	Mortgage-backed securities	607		4		1		610		Mortgage-backed securities	622		—		24		598
Asset-backed securities										Asset-backed securities	261		—		9		252
U.S. Treasury notes	U.S. Treasury notes	235		—		—		235		U.S. Treasury notes	174		—		—		174
Asset-backed securities		223		1		—		224
Municipal securities	Municipal securities	96		1		—		97		Municipal securities	123		—		6		117

Other	Other	29		—		—		29		Other	40		—		1		39
Total	Total	$	2,878	$	25	$	3	$	2,900	Total	$	3,094	$	1	$	107	$	2,988


		December 31, 2020									December 31, 2021
		Amortized Cost		Gross Unrealized				Estimated Fair Value			Amortized Cost		Gross Unrealized				Estimated Fair Value
				Gains		Losses							Gains		Losses

		(In millions)									(In millions)
Corporate debt securities	Corporate debt securities	$	1,220	$	36	$	—	$	1,256	Corporate debt securities	$	1,836	$	9	$	12	$	1,833
Mortgage-backed securities	Mortgage-backed securities	383		10		1		392		Mortgage-backed securities	616		2		4		614
Asset-backed securities										Asset-backed securities	248		—		1		247
U.S. Treasury notes	U.S. Treasury notes	27		—		—		27		U.S. Treasury notes	353		—		—		353
Asset-backed securities		130		2		—		132
Municipal securities	Municipal securities	66		2		—		68		Municipal securities	123		1		1		123

Other										Other	32		—		—		32
Total	Total	$	1,826	$	50	$	1	$	1,875	Total	$	3,208	$	12	$	18	$	3,202

The contractual maturities of our ~~available-for-sale~~current investments as of ~~September 30, 2021~~March 31, 2022 are summarized below:


		Amortized Cost		Estimated Fair Value			Amortized Cost		Estimated Fair Value

		(In millions)					(In millions)
Due in one year or less	Due in one year or less	$	555	$	557	Due in one year or less	$	466	$	466
Due after one year through five years	Due after one year through five years	1,530		1,546		Due after one year through five years	1,733		1,668
Due after five years through ten years	Due after five years through ten years	296		298		Due after five years through ten years	318		306
Due after ten years	Due after ten years	497		499		Due after ten years	577		548
Total	Total	$	2,878	$	2,900	Total	$	3,094	$	2,988

Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains ~~amounted to $6 million~~ and $7 million for the three and nine months ended September 30, 2021, respectively. Gross realized investment gains were insignificant for three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment losses were insignificant for the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, and ~~2020.~~2021.

We have determined that unrealized losses at ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1413

Table of Contents

The following table summarizes those available-for-sale investments that have been in a continuous loss position for less than 12 months. No investments have been in a continuous loss position for 12 months or more as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020.~~2021.


		September 30, 2021					December 31, 2020						March 31, 2022					December 31, 2021
		Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions		Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions

		(Dollars in millions)											(Dollars in millions)
Corporate debt securities	Corporate debt securities	$	509	$	2	174	$	—	$	—	—	Corporate debt securities	$	1,516	$	67	624	$	1,063	$	12	395
Mortgage-backed securities	Mortgage-backed securities	270		1		94	77		1		21	Mortgage-backed securities	582		24		238	408		4		146
Asset-backed securities												Asset-backed securities	208		9		99	166		1		75

Municipal securities												Municipal securities	97		6		120	69		1		61
Other												Other	25		1		10	—		—		—

Total	Total	$	779	$	3	268	$	77	$	1	21	Total	$	2,428	$	107	1,091	$	1,706	$	18	677

Restricted Investments Held-to-Maturity

Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as “Restricted investments” in the accompanying consolidated balance sheets.

We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to ~~$156~~$221 million at ~~September 30, 2021,~~March 31, 2022, of which ~~$148~~$190 million will mature in one year or less, and $8$31 million will mature ~~after~~in one through five years.

7. Medical Claims and Benefits Payable

The following table provides the details of our medical claims and benefits payable as of the dates indicated:


		September 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021

		(In millions)					(In millions)
Fee-for-service claims incurred but not paid (“IBNP”)		$	2,246	$	1,647
Claims incurred but not paid (“IBNP”)						Claims incurred but not paid (“IBNP”)	$	2,521	$	2,486
Pharmacy payable	Pharmacy payable	209		157		Pharmacy payable	240		219
Capitation payable	Capitation payable	86		70		Capitation payable	95		82
Other	Other	650		528		Other	745		576
Magellan Complete Care acquisition opening balance		—		294
Total	Total	$	3,191	$	2,696	Total	$	3,601	$	3,363

“Other” medical claims and benefits payable ~~includes~~include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to ~~$301~~$322 million and ~~$235~~$226 million as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, respectively.

The following ~~table presents~~tables present the components of the change in our medical claims and benefits payable for the periods ~~indicated, with the prior period recast to conform to the current year presentation.~~indicated. The amounts presented for “Components of medical care costs related to: Prior years” represent ~~decreases in~~the amount by which our original estimate of medical ~~care costs resulting~~claims and benefits payable at the beginning of the year varied from the actual ~~medical care costs being less than we previously estimated in~~liabilities, based on information (principally the ~~prior year.~~payment of claims) developed since those liabilities were first reported.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1514

Table of Contents


		Nine Months Ended September 30, 2021									Three Months Ended March 31, 2022
		Medicaid		Medicare		Marketplace		Consolidated			Medicaid		Medicare		Marketplace		Consolidated

		(In millions)									(In millions)
Medical claims and benefits payable, beginning balance	Medical claims and benefits payable, beginning balance	$	2,129	$	392	$	175	$	2,696	Medical claims and benefits payable, beginning balance	$	2,580	$	404	$	379	$	3,363
Components of medical care costs related to:	Components of medical care costs related to:									Components of medical care costs related to:
Current year	Current year	13,491		2,195		1,872		17,558		Current year	5,424		840		505		6,769
Prior years	Prior years	(158)		(36)		(22)		(216)		Prior years	(154)		(25)		(27)		(206)
Total medical care costs	Total medical care costs	13,333		2,159		1,850		17,342		Total medical care costs	5,270		815		478		6,563
Payments for medical care costs related to:	Payments for medical care costs related to:									Payments for medical care costs related to:
Current year	Current year	11,530		1,816		1,534		14,880		Current year	3,402		465		330		4,197
Prior years	Prior years	1,538		340		130		2,008		Prior years	1,633		306		260		2,199
Total paid	Total paid	13,068		2,156		1,664		16,888		Total paid	5,035		771		590		6,396
Change in acquired balances		(19)		(8)		—		(27)
Acquired balances, net of post-acquisition adjustments										Acquired balances, net of post-acquisition adjustments	(25)		—		—		(25)
Change in non-risk and other provider payables	Change in non-risk and other provider payables	68		—		—		68		Change in non-risk and other provider payables	93		3		—		96
Medical claims and benefits payable, ending balance	Medical claims and benefits payable, ending balance	$	2,443	$	387	$	361	$	3,191	Medical claims and benefits payable, ending balance	$	2,883	$	451	$	267	$	3,601


	Three Months Ended March 31, 2021
	Medicaid		Medicare		Marketplace		Consolidated

	(In millions)
Medical claims and benefits payable, beginning balance	$	2,129	$	392	$	175	$	2,696
Components of medical care costs related to:
Current year	4,394		738		536		5,668
Prior years	(158)		(16)		(20)		(194)
Total medical care costs	4,236		722		516		5,474
Payments for medical care costs related to:
Current year	2,790		410		313		3,513
Prior years	1,364		304		113		1,781
Total paid	4,154		714		426		5,294
Acquired balances, net of post-acquisition adjustments	8		(33)		—		(25)
Change in non-risk and other provider payables	(11)		(1)		—		(12)
Medical claims and benefits payable, ending balance	$	2,208	$	366	$	265	$	2,839

Nine Months Ended September 30, 2020
Medicaid Medicare Marketplace Consolidated
(In millions)
Medical claims and benefits payable, beginning balance $ 1,465 $ 267 $ 122 $ 1,854
Components of medical care costs related to:
Current year 9,029 1,588 861 11,478
Prior years (41) (25) — (66)
Total medical care costs 8,988 1,563 861 11,412
Payments for medical care costs related to:
Current year 7,470 1,316 714 9,500
Prior years 1,193 233 101 1,527
Total paid 8,663 1,549 815 11,027
Change in non-risk and other provider payables 50 — — 50
Medical claims and benefits payable, ending balance $ 1,840 $ 281 $ 168 $ 2,289

Our estimates of medical claims and benefits payable recorded at December 31, ~~2020,~~2021, and ~~2019~~2020 developed favorably by approximately ~~$216~~$206 million and ~~$66~~$194 million as of ~~September 30,~~March 31, 2022, and 2021, ~~and 2020,~~ respectively.

The favorable prior ~~period~~year development recognized in the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance. Consequently, the ultimate costs recognized in ~~2021,~~2022, as claims payments were processed, were lower than our ~~previous~~ estimates in ~~2020.~~2021.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1615

Table of Contents

8. Debt

All ~~long-term~~our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:


		September 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021

		(In millions)					(In millions)

Non-current long-term debt:	Non-current long-term debt:					Non-current long-term debt:
4.375% Notes due 2028	4.375% Notes due 2028	$	800	$	800	4.375% Notes due 2028	$	800	$	800
5.375% Notes due 2022		700		700
3.875% Notes due 2030	3.875% Notes due 2030	650		650		3.875% Notes due 2030	650		650
3.875% Notes due 2032						3.875% Notes due 2032	750		750
Deferred debt issuance costs	Deferred debt issuance costs	(20)		(23)		Deferred debt issuance costs	(26)		(27)
Total	Total	$	2,130	$	2,127	Total	$	2,174	$	2,173

Credit Agreement

We are party to a credit agreement ~~(“Credit~~(the “Credit Agreement”) which includes a revolving credit facility (“Credit Facility”) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee.

The Credit Agreement contains customary non-financial and financial covenants. As of ~~September 30, 2021,~~March 31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of ~~September 30, 2021,~~March 31, 2022, no amounts were outstanding under the Credit Facility.

~~High-Yield~~ Senior Notes

Our ~~high-yield~~ senior notes are described below. Each of these notes are senior unsecured obligations of Molina ~~Healthcare,~~ and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of ~~Molina Healthcare.~~Molina. In addition, each of the notes ~~contains~~contain customary non-financial covenants and change of control provisions.

The indentures governing the ~~high-yield~~ senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture.

4.375% Notes due 2028. We had $800 million aggregate principal amount of senior notes (the “4.375% Notes”) outstanding as of ~~September 30, 2021,~~March 31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15.

~~5.375%~~3.875% Notes due ~~2022.~~2030. We had ~~$700~~$650 million aggregate principal amount of senior notes (the ~~“5.375% Notes”~~“3.875% Notes due 2030”) outstanding as of ~~September 30, 2021,~~March 31, 2022, which are due November 15, ~~2022,~~2030, unless earlier redeemed. Interest, at a rate of ~~5.375%~~3.875% per annum, is payable semiannually in arrears on May 15 and November 15.

3.875% Notes due ~~2030.~~ 2032.We had ~~$650~~$750 million aggregate principal amount of senior notes (the “3.875% ~~Notes”~~Notes due 2032”) outstanding as of ~~September 30, 2021,~~March 31, 2022, which are due ~~November~~May 15, ~~2030,~~2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.

9. Stockholders' Equity

In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program, ~~immediately supersedes~~which superseded the stock purchase program ~~previously~~ approved by our board of directors in September ~~2020. This new program will be~~2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of ~~October 28, 2021, no~~April 27, 2022, we have purchased 85,000 shares ~~had been purchased~~ under the stock purchase program approved in 2021.

In September 2020, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 1716

Table of Contents

plan, we purchased approximately 577,000 shares for $122 million in January and February 2021 (average cost of $211.65). In November and December 2020, we purchased 766,000 shares of our common stock for $159 million (average cost of $208.37), including approximately 29,000 shares purchased for $6 million in late December 2020, and settled in early January 2021.

10. Segments

~~In the first quarter of 2021, we realigned our~~We currently have 4 reportable ~~operating~~ segments ~~to reflect recent changes in our internal operating~~consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is4) Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. ~~These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.~~

The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes certain corporate amounts not associated with or allocated to the Medicaid, Medicare, or Marketplace segments. Additionally, the Other segment includes service revenues and service costs associated with the long-term services and supports consultative services we ~~now~~ provide in ~~Wisconsin, as a result of the Magellan Complete Care acquisition on December 31, 2020.~~Wisconsin.

The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and medical care ratio (“MCR”). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment because this is not a metric used to assess segment performance or allocate resources.

~~For all tables presented below, the prior period disclosures have been recast to conform to the current period segment presentation.~~

The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.

Three Months Ended September 30, Nine Months Ended September 30,
2021 2020 2021 2020
(In millions)
Total revenue:
Medicaid $ 5,354 $ 3,996 $ 15,583 $ 11,124
Medicare 875 636 2,502 1,909
Marketplace 793 389 2,224 1,155
Other 18 — 53 —
Total $ 7,040 $ 5,021 $ 20,362 $ 14,188

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 18~~

~~Table of Contents~~

The following table presents goodwill and intangibles assets, net by segment. For the Magellan Complete Care acquisition completed on December 31, 2020, the total purchase price was preliminarily allocated to tangible and intangible assets acquired, and liabilities assumed, based on their fair values as of the acquisition date. We expect to complete the final determination of the purchase price allocation no later than December 31, 2021, which may result in adjustments to the related goodwill and intangible assets, net.


		September 30,		December 31,			Three Months Ended March 31,
		2021		2020			2022		2021

		(In millions)					(In millions)
Goodwill:
Total revenue:						Total revenue:
Medicaid	Medicaid	$	387	$	378	Medicaid	$	6,187	$	5,020
Medicare	Medicare	247		247		Medicare	949		805
Other		67		67
Intangibles assets, net:
Medicaid		135		157
Medicare		65		76
Marketplace						Marketplace	616		680
Other	Other	14		16		Other	18		17
Total	Total	$	915	$	941	Total	$	7,770	$	6,522

The following table reconciles margin by segment to consolidated income before income taxes.


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended March 31,
		2021		2020		2021		2020			2022		2021

		(In millions)									(In millions)
Margin:	Margin:									Margin:
Medicaid	Medicaid	$	532	$	509	$	1,687	$	1,427	Medicaid	$	710	$	604
Medicare	Medicare	151		91		329		333		Medicare	128		77
Marketplace	Marketplace	68		70		331		272		Marketplace	130		151
Other	Other	4		—		11		—		Other	3		4
Total margin	Total margin	755		670		2,358		2,032		Total margin	971		836
Add: other operating revenues (1)	Add: other operating revenues (1)	222		253		620		744		Add: other operating revenues (1)	221		199
Less: other operating expenses (2)	Less: other operating expenses (2)	(756)		(634)		(2,149)		(1,789)		Less: other operating expenses (2)	(820)		(700)
Operating income	Operating income	221		289		829		987		Operating income	372		335
Other expenses, net	Other expenses, net	30		27		90		77		Other expenses, net	28		30
Income before income tax expense	Income before income tax expense	$	191	$	262	$	739	$	910	Income before income tax expense	$	344	$	305

______________________

(1)Other operating revenues include premium tax revenue, ~~health insurer fees reimbursed,~~ investment income, and other revenue.

(2)Other operating expenses include general and administrative expenses, premium tax expenses, ~~health insurer fees,~~ depreciation and amortization, and other operating expenses.

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 17

Table of Contents

11. Commitments and Contingencies

COVID-19 Pandemic

We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will ~~continue to~~ be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 19~~

~~Table of Contents~~

Legal Proceedings

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. ~~The consequences~~Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, ~~and~~ the repayment of previously billed and collected ~~revenues.~~revenues and reputational damage.

We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.

Kentucky RFP. On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including ~~Molina Healthcare of~~our Kentucky ~~Inc., Civil Action No. 20-CI-00719. On October 23, 2020, the Court issued a temporary injunction directing that open enrollment for 2021 proceed with six~~ health ~~plans, including both Molina Healthcare of Kentucky and Anthem.~~plan. The new Medicaid contracts commenced on January 1, 2021. On April 28, 2021, the Court issued its preliminary Opinion and Order, which Opinion and Order the Court finalized on June 16, 2021. Under the final Order, which the Court indicated is immediately appealable by the parties, the Court, among other things, upheld the validity of the RFP award to Molina, and also upheld the validity of Molina’s acquisition of the assets of Passport in September 2020. Due to various perceived scoring irregularities, however, the Court ordered a new RFP, with the status quo of six health plans serving Kentucky Medicaid members to continue in the interim. On July 15-16, 2021, each of United, Molina, Humana, and Aetna filed notices of appeal. On July 23, 2021, both the Kentucky Finance and Administration Cabinet and the Kentucky Cabinet for Health and Family Services filed notices of cross appeal, and on July 26, 2021, Anthem filed a notice of cross appeal. This matter remains subject to potential additional legal and appellate ~~proceedings,~~briefing has concluded and no assurances can be given regarding the ultimate outcome. Under the Court’s June 16, 2021 final Order, ~~Molina Healthcare of~~our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract and provide care to Kentucky Medicaid members.

Puerto Rico. On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. ~~(MHPR)~~(“MHPR”) filed a complaint asserting, among other claims, breach of contract against the Puerto Rico Health Insurance Administration ~~(ASES)~~(“ASES”). On September 13, 2021, in addition to filing its answer to MHPR’s complaint, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. The counterclaim alleges that MHPR and the Company breached contractual obligations by failing to pay providers, and ~~in addition to~~seeks damages ~~seeks~~and various equitable remedies. On October 8, 2021, MHPR filed its reply to the counterclaim, denying all the ~~allegations.~~allegations, and on November 1, 2021, the Company filed its answer to the third-party complaint. On December 3, 2021, MHPR filed a request for disbursement of illegally withheld funds, and ASES filed its opposition. At a status hearing on January 19, 2022, the Court heard MHPR’s request for disbursement. The Court has not ruled on the request. On March 23, 2022, the Court informed the parties that it will appoint a Special Commissioner to review the merits of the entire case, with the assigned judge retaining final authority over any resolution. The parties are negotiating the engagement of the Special Commissioner. This matter is in its early stages and remains subject to significant additional proceedings, and no prediction can be made as to the outcome. No gain or loss is probable and reasonably estimable with regard to either MHPR’s complaint or the counterclaim of ASES.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2018

Table of Contents

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (“MD&A”)

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section 27A of the Securities Act of 1933, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “guidance,” “future,” “anticipates,” “believes,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled “Risk Factors” in our ~~2020~~2021 Annual Report on Form 10-K, including without limitation the following:

•the impact of the COVID-19 pandemic and its associated or indirect effects on our business, operations, and financial results, including without limitation the duration of the Public Health Emergency Declaration (“PHE”) and associated suspension in redeterminations, and the potential impact on our workforce or contractors of federal or state vaccine mandates;

•significant budget pressures on state governments from diminished tax revenues incidental to the COVID-19 pandemic and their efforts to reduce rates or limit rate increases, to impose profit caps or risk corridors, or to recoup previously paid premium amounts on a retroactive basis;

•the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the “ACA”);

•the market dynamics surrounding the ACA Marketplaces, including issues impacting enrollment, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;

•the outcome of the legal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan and our acquisition of certain assets of Passport;

•the success of our efforts to retain existing or awarded government contracts, and the success of any bid submissions in response to requests for proposal, including our contracts in California and Texas;

•subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment;

•our ability to consummate, integrate, and realize benefits from acquisitions, including the completed acquisitions of Magellan Complete Care, Passport, ~~and~~ Affinity, ~~and the announced acquisitions of AgeWell New York~~ and the Medicaid assets of Cigna in ~~Texas;~~Texas, and the announced acquisition of AgeWell New York;

•effective management of our medical costs;

•our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19;

•cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected information;

•the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives;

•our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs;

•our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs;

•the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements;

•our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements;

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2119

Table of Contents

•the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members;

•the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith;

•the success and renewal of our ~~Medicare-Medicaid Plan (“MMP”)~~duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas;

•the accurate estimation of incurred but not reported or paid medical costs across our health plans;

•efforts by states to recoup previously paid and recognized premium amounts;

•changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;

•complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;

•fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;

•our exit from Puerto Rico, including the payment in full of our outstanding accounts receivable, the effective run-out of claims, the return of our capital, and the outcome of the claims filed against our Puerto Rico health plan and us by the Puerto Rico Health Insurance Administration, or ASES;

•changes with respect to our provider contracts and the loss of providers;

•approval by state regulators of dividends and distributions by our health plan subsidiaries;

•changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;

•high dollar claims related to catastrophic illness;

•the resolution, favorable or unfavorable, of litigation, arbitration, or administrative proceedings;

•the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;

•the failure to comply with the financial or other covenants in ~~the Credit Agreement~~our credit agreement or the indentures governing our outstanding notes;

•the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;

•the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;

•the failure of a state in which we operate to renew its federal Medicaid waiver;

•changes generally affecting the managed care industry;

•increases in government surcharges, taxes, and assessments;

•the unexpected loss of the leadership of one or more of our senior executives; and

•increasing competition and consolidation in the Medicaid industry.

Each of the terms “Molina Healthcare, Inc.” “Molina Healthcare,” “Company,” “we,” “our,” and “us,” as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Readers should refer to the section entitled “Risk Factors” in our ~~2020~~2021 Annual Report on Form 10-K, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.

This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management’s Discussion and Analysis appearing in our ~~2020~~2021 Annual Report on Form 10-K.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2220

Table of Contents

OVERVIEW

Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 155), provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the “Marketplace”). We served approximately ~~4.8~~5.1 million members as of ~~September 30, 2021.~~March 31, 2022, located across 19 states.

~~THIRD~~FIRST QUARTER ~~2021~~2022 HIGHLIGHTS

We reported net income of ~~$143~~$258 million, or ~~$2.46~~$4.39 per diluted share, for the ~~third~~first quarter of ~~2021,~~2022, which reflected the following:

•Membership increase of ~~0.8 million,~~480,000, or ~~20%~~10%, compared with ~~September 30, 2020,~~March 31, 2021, and a ~~142,000~~114,000 sequential ~~increase~~decrease compared to ~~June 30,~~December 31, 2021;

•Premium revenue of ~~$6.8~~$7.5 billion ~~which~~ increased ~~43%~~19% compared with the ~~third~~first quarter of ~~2020,~~2021, reflecting increased organic membership in ~~all lines of business,~~Medicaid and Medicare, along with the impact of ~~acquisitions;~~acquisitions, partially offset by the decline in Marketplace membership;

•Consolidated medical care ratio (“MCR”) was ~~88.9%~~87.1%, compared with ~~85.9%~~86.8% for the ~~third~~first quarter of ~~2020,~~2021, and increased due to the net effect of COVID, which increased the MCR by ~~110~~50 basis points in the ~~third~~first quarter of ~~2021,~~2022, but was ~~slightly positive~~negligible in the ~~third~~first quarter of ~~2020;~~2021;

•General and administrative expense (“G&A”) ratio of ~~7.5%~~7.4%, which ~~increased~~ compared with 7.3% in the ~~third~~first quarter of ~~2020,~~2021, reflecting temporary labor costs challenges, certain non-recurring costs and appropriate investments to ~~support our business~~accommodate growth, ~~and increased acquisition-related expenses,~~ partially offset by the benefits of ~~revenue growth and continued discipline~~scale produced by our increase in ~~cost management;~~revenue; and

•After-tax margin of ~~2.0%~~3.3%, which ~~met~~was in line with our expectations.

We note the following factors impacting the ~~2021 third~~2022 first quarter financial results:

•We estimate that the net effect of COVID decreased net income by approximately ~~$1.00~~$0.57 per diluted share in the ~~third~~first quarter of ~~2021.~~2022. The net effect of COVID ~~was slightly positive in~~had a negligible impact on the ~~third~~first quarter of ~~2020.~~2021.

•The net effect of COVID reflects higher COVID inpatient costs, lower COVID-related utilization curtailment and the impact of the COVID risk-sharing corridors, and impacted all of our ~~segments.~~

•We experienced higher than expected membership increases in Marketplace. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, andsegments during the ~~extended open enrollment period, as described in further detail below in “Trends and Uncertainties.”~~first quarter of 2022.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2321

Table of Contents

CONSOLIDATED FINANCIAL SUMMARY


		Three Months Ended September 30,						Nine Months Ended September 30,							Three Months Ended March 31,
		2021			2020			2021			2020				2022			2021

		(In millions, except per-share amounts)													(In millions, except per-share amounts)
Premium revenue	Premium revenue	$	6,800		$	4,768		$	19,689		$	13,444		Premium revenue	$	7,531		$	6,306
Less: medical care costs	Less: medical care costs	6,049			4,098			17,342			11,412			Less: medical care costs	6,563			5,474
Medical margin	Medical margin	751			670			2,347			2,032			Medical margin	968			832
MCR (1)	MCR (1)	88.9		%	85.9		%	88.1		%	84.9		%	MCR (1)	87.1		%	86.8		%

Other revenues:	Other revenues:													Other revenues:
Premium tax revenue	Premium tax revenue	204			170			576			477			Premium tax revenue	208			187
Health insurer fees reimbursed		—			69			—			206

Investment income	Investment income	20			10			39			48			Investment income	11			9
Other revenue	Other revenue	16			4			58			13			Other revenue	20			20

General and administrative expenses	General and administrative expenses	532			368			1,489			1,030			General and administrative expenses	571			473
G&A ratio (2)	G&A ratio (2)	7.5		%	7.3		%	7.3		%	7.3		%	G&A ratio (2)	7.4		%	7.3		%

Premium tax expenses	Premium tax expenses	204			170			576			477			Premium tax expenses	208			187
Health insurer fees		—			70			—			209

Depreciation and amortization	Depreciation and amortization	32			23			96			64			Depreciation and amortization	40			33
Other	Other	2			3			30			9			Other	16			20
Operating income	Operating income	221			289			829			987			Operating income	372			335
Interest expense	Interest expense	30			27			90			72			Interest expense	28			30
Other expense, net		—			—			—			5

Income before income tax expense	Income before income tax expense	191			262			739			910			Income before income tax expense	344			305
Income tax expense	Income tax expense	48			77			183			271			Income tax expense	86			77
Net income	Net income	$	143		$	185		$	556		$	639		Net income	$	258		$	228

Net income per share – Diluted	Net income per share – Diluted	$	2.46		$	3.10		$	9.51		$	10.65		Net income per share – Diluted	$	4.39		$	3.89

Diluted weighted average shares outstanding	Diluted weighted average shares outstanding	58.5			59.6			58.5			60.0			Diluted weighted average shares outstanding	58.7			58.6

Other Key Statistics	Other Key Statistics													Other Key Statistics
Ending membership	Ending membership	4.8			4.0			4.8			4.0			Ending membership	5.1			4.6
Effective income tax rate	Effective income tax rate	24.8		%	29.5		%	24.7		%	29.8		%	Effective income tax rate	25.0		%	25.2		%
After-tax margin (3)	After-tax margin (3)	2.0		%	3.7		%	2.7		%	4.5		%	After-tax margin (3)	3.3		%	3.5		%

________________________

(1) MCR represents medical care costs as a percentage of premium revenue.

(2) G&A ratio represents general and administrative expenses as a percentage of total revenue.

(3) After-tax margin represents net income as a percentage of total revenue.

CONSOLIDATED RESULTS

NET INCOME AND OPERATING INCOME

Net income in the ~~third~~first quarter of ~~2021~~2022 amounted to ~~$143~~$258 million, or ~~$2.46~~$4.39 per diluted share, compared with ~~$185~~$228 million, or ~~$3.10~~$3.89 per diluted share, in the ~~third quarter of 2020. We estimate that the net effect of COVID decreased net income by approximately $1.00 per diluted share in the third~~first quarter of 2021. InThe 13% increase in net income is consistent with the ~~third quarter of 2020, the net effect of COVID had a slightly positive impact on earnings.~~

~~Operating~~improvement in operating income, ~~of $221~~which increased to $372 million in the ~~third~~first quarter of ~~2021, was lower~~2022, compared with ~~$289~~$335 million in the ~~third~~first quarter of ~~2020.~~2021.

~~Net~~The improvement in operating income was mainly due to membership growth and higher premium revenues, partially offset by an increase in the ~~nine months ended September 30, 2021 amounted to $556 million,~~MCR.

PREMIUM REVENUE

Premium revenue increased $1.2 billion, or ~~$9.51 per diluted share,~~19%, in the first quarter of 2022, when compared with ~~$639 million, or $10.65 per diluted share,~~the first quarter of 2021. The higher premium revenue reflects increased organic membership in the ~~nine months ended September 30, 2020. Operating~~Medicaid and Medicare segments and the impact of acquisitions, partially offset by a decline in the Marketplace segment. The increase in premium

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2422

Table of Contents

~~income of $829 million in the nine months ended September 30, 2021, was lower compared with $987 million in the nine months ended September 30, 2020.~~

~~The decrease in operating income for both periods was mainly due to the increase in MCR, due primarily to the net effect of COVID, partially offset by membership growth and higher premium revenues.~~

The year-over-year comparison between 2020 and 2021 is significantly impacted by the positive net effect of COVID that characterized the relatively early phases of the pandemic in the second and third quarters of 2020.

Net income per share in the third quarter and nine months ended September 30, 2021 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchases in late 2020 and early 2021. See further discussion in “Liquidity and Financial Condition,” below.

~~PREMIUM REVENUE~~

Premium revenue increased $2.0 billion, or 43%, in the third quarter of 2021, when compared with the third quarter of 2020, and increased $6.2 billion, or 46%, in the nine months ended September 30, 2021, when compared with the nine months ended September 30, 2020.

Membership increased by 805,000 compared with September 30, 2020, which mainly reflected organic increases in the Medicaid and Marketplace segments and the impact from the Magellan Complete Care and other acquisitions that closed in the second half of 2020. The increase in premium revenue was ~~net~~partially attributable to a reduced impact of COVID-related risk corridors that ~~have been~~were enacted in several states beginning in the second quarter of 2020.

MEDICAL CARE RATIO

The consolidated MCR in the ~~third~~first quarter of ~~2021~~2022 was ~~88.9%~~87.1%, compared with ~~85.9%~~86.8% in the ~~third~~first quarter of ~~2020.~~2021. The Medicaid and Marketplace MCRs increased in the first quarter of 2022, while the Medicare MCR decreased. The net effect of COVID increased the consolidated MCR in the first quarter of 2022 by approximately ~~110~~50 basis points ~~in the third quarter of 2021, and reflects higher COVID inpatient costs, lower COVID-related utilization curtailment and the impact of the risk-sharing corridors,~~ and impacted all ~~our segments. In~~segments in the ~~prior year the~~first quarter of 2022. The net effect of COVID had a ~~slightly favorable~~negligible impact toon the ~~consolidated MCR.~~

The consolidated MCR in the nine months ended September 30, 2021 was 88.1%, compared with 84.9% in the nine months ended September 30, 2020. Similar to the quarter-to-date consolidated MCR, the increase is due to the net effectfirst quarter of ~~COVID; however, the~~2021. The impacts were varied by ~~segment.~~segment in both periods.

The prior year reserve development in the ~~third~~first quarter ~~and nine months ended September 30, 2021~~of 2022 was modestly favorable, but its impact on earnings was ~~mostly~~ absorbed by the COVID-related risk corridors.

PREMIUM TAX REVENUE AND EXPENSES

The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was ~~2.9%~~2.7% and ~~3.4%~~2.9% for the ~~third~~first quarter of ~~2021~~2022 and ~~2020, respectively, and 2.8% and 3.4% for the nine months ended September 30,~~ 2021, ~~and 2020,~~ respectively. The current year ratio decrease was mainly due to changes in business ~~mix resulting from the Magellan Complete Care and other acquisitions closed in the second half of 2020.~~mix.

INVESTMENT INCOME

Investment income increased to ~~$20~~$11 million in the ~~third~~first quarter of 2022, compared with $9 million in the first quarter of 2021, ~~compared with $10 million~~mainly due to an increase in interest rates and higher levels of invested assets. Investment yields were lower in the ~~third~~first quarter of ~~2020,~~2021 due to higher invested assets and increased realized gains. Investment income decreased to $39 million in the nine months ended September 30, 2021, compared with $48 million in the nine months ended September 30, 2020. The year-over-year decrease was due to the continued low interest rate environment and a ~~temporarily higher~~temporary allocation in shorter-term invested assets ~~during~~due to the COVID-19 pandemic, ~~which~~until it was rescinded ~~effective for~~in the second quarter of 2021.

OTHER REVENUE

Other revenue ~~increased to $16~~was consistent at $20 million in the third quarter of 2021, compared with $4 million in the third quarter of 2020, and increased to $58 million in the nine months ended September 30, 2021, compared with $13 million in the nine months ended September 30, 2020. Beginning in the first quarter of ~~2021, other~~2022 and 2021. Other revenue mainly includes service revenue associated with ~~the~~ long-term services and supports consultative services we ~~now~~ provide in ~~Wisconsin, as a result of our Magellan Complete Care acquisition.~~

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 25~~

~~Table of Contents~~

Wisconsin.

G&A EXPENSES

The G&A expense ratio ~~increased to 7.5%~~was 7.4% in the ~~third~~first quarter of ~~2021,~~2022, compared with 7.3% in the ~~third~~first quarter of ~~2020. The G&A expense ratio was 7.3% in the nine months ended September 30,~~ 2021, ~~consistent with the nine months ended September 30, 2020. The year over year comparisons for both periods are impacted by~~mainly reflecting temporary labor cost challenges, certain non-recurring costs and appropriate investments to ~~support our business~~accommodate growth, ~~and increased acquisition-related expenses,~~ partially offset by ~~continued discipline~~the benefits of scale produced by our increase in ~~cost management and increased revenues.~~

~~HEALTH INSURER FEES (“HIF”)~~

~~There were no HIF fees incurred or reimbursed in 2021, because the HIF was repealed effective for years after 2020.~~revenue. We expect our full year 2022 G&A ratio to be consistent with our long term targets.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization increased to ~~$32~~$40 million in the ~~third~~first quarter of ~~2021,~~2022, compared with ~~$23~~$33 million in the ~~third~~first quarter of ~~2020, and increased to $96 million in the nine months ended September 30,~~ 2021, ~~compared with $64 million in the nine months ended September 30, 2020. The increases in both periods were~~ due primarily to amortization associated with recent acquisitions completed in the ~~second half~~fourth quarter of ~~2020.~~

~~Refer to Notes to Consolidated Financial Statements, Note 10, “Segments,” for further information.~~2021 and the first quarter of 2022.

OTHER OPERATING EXPENSES

Other operating expenses ~~decreased to $2~~totaled $16 million in the third quarter of 2021, compared with $3 million in the third quarter of 2020, and increased to $30 million in the nine months ended September 30, 2021, compared with $9 million in the nine months ended September 30, 2020. Beginning in the first quarter of ~~2021, other~~2022, compared with $20 million in the first quarter of 2021. Other operating expenses ~~include~~mainly includes service costs associated with ~~the~~ long-term services and supports consultative services we ~~now~~ provide in Wisconsin, as noted above.

INTEREST EXPENSE

Interest expense ~~increased~~decreased to $28 million in the first quarter of 2022, compared with $30 million in the ~~third~~first quarter of ~~2021, compared with $27~~2021. The decrease resulted from our early redemption of $700 million ~~in the third quarter of 2020, and to $90 million in the nine months ended September 30, 2021, compared with $72 million in the nine months ended September 30, 2020, mainly due to the $650 million~~aggregate principal amount of ~~3.875% Notes issued~~our 5.375% senior notes due 2022 in the fourth quarter of ~~2020.~~

~~See further details~~2021, partially offset by interest related to the private offering of ~~our financing transactions~~the 3.875% Notes due 2032 in ~~Notes to Consolidated Financial Statements, Note 8, “Debt,” and below in “Liquidity and Financial Condition.”~~the same period.

INCOME TAXES

Income tax expense amounted to ~~$48~~$86 million in the ~~third~~first quarter of ~~2021,~~2022, or ~~24.8%~~25.0% of pretax income, compared with income tax expense of $77 million, or ~~29.5%~~25.2% of pretax income in the ~~third~~first quarter of ~~2020. Income tax expense amounted to $183 million~~2021. The difference in the ~~nine months ended September 30, 2021, or 24.7% of pretax income, compared with income tax expense of $271 million, or 29.8% of pretax income in the nine months ended September 30, 2020. The~~ effective tax rate is ~~lower~~primarily due to the impact of certain discrete tax benefits recognized in ~~2021 mainly because~~ the ~~nondeductible HIF was repealed for years after 2020.~~three months ended March 31, 2022.

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 23

Table of Contents

TRENDS AND UNCERTAINTIES

COVID-19 PANDEMIC

As the COVID-19 pandemic continues to evolve, its ongoing impact to our business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Medicaid, Medicare, and Marketplace segments follow.

Federal Economic Stabilization and Other Programs

~~In addition to various programs enacted in 2020 and described in our 2020 Annual Report on Form 10-K, the $1.9 trillion~~ ~~American Rescue Plan Act of 2021~~ was enacted on March 11, 2021. This legislation includes several components to assist in COVID-19 vaccine testing and deployment, as well as provisions relating to the opening of schools; direct immediate relief to working families; and additional support for communities struggling in the wake of the pandemic. Among its specific provisions:

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 26~~

~~Table of Contents~~

•~~$350 billion in state and local funding;~~

•~~Funding for Medicaid and CHIP COVID-19 vaccines and treatment to be matched at 100% of the federal medical assistance percentage (“FMAP”);~~

•~~Incentives for states that have not expanded Medicaid to do so;~~

•~~State flexibility to extend Medicaid eligibility to women for 12 months postpartum;~~

•~~A temporary 10% FMAP increase for states to improve Medicaid home- and community-based services for one year; and~~

•~~An increase to the ACA Marketplace premium subsidies for 2021 and 2022.~~

~~In addition,~~Effective January 16, 2022, the Biden Administration ~~has~~ extended the COVID-19 related ~~PHE. The Biden Administration has indicated the~~ PHE, will likely remain in place throughout 2021, and that states will receive 60 days’ notice before the end of the PHE to prepare for the end of emergency authorities and the resumption of pre-PHE rules. This extension of the PHE will continuewhich, among other things, continued the suspension in state Medicaid eligibility ~~redeterminations.~~

~~Also, President Biden’s January 2021 executive order providing~~redeterminations for ~~a three-month Marketplace special enrollment period from February~~90 days until April 16, 2022. Effective April 17, 2022, the Biden Administration extended the PHE for another 90 days and it will remain in effect until July 15, 2021 to May 15, 2021, was extended through August 15, 2021. This SEP has now ended in all of our states except for California, where the state-run exchange intends to keep it in place for the remainder of the 2021 benefit year, which ends on December 31, 2021.2022, unless extended.

Due to the uncertainty as to the duration and breadth of the pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization and other programs to our business, financial condition, and operating results.

Operations

Enrollment and Premium Revenue

Excluding acquisitions and our exit from Puerto Rico, we ~~have~~ added over ~~700,000~~750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through ~~mid-January~~mid-July 2022.

~~Marketplace revenue growth is now expected~~Beginning in 2020, various states enacted temporary risk corridors in response to ~~be over 90%~~the reduced demand for medical services stemming from COVID-19, which have resulted in ~~2021, and we expect to end 2021 with approximately 680,000 members.~~

a reduction of our medical margin. The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. In the ~~third quarter and the nine~~three months ended ~~September 30, 2021,~~March 31, 2022, we recognized approximately ~~$17~~$28 million, ~~and $183 million, respectively,~~ for the impact of these risk corridors, ~~enacted in several states beginning~~compared to $110 million recognized in the ~~second quarter of 2020, in response~~three months ended March 31, 2021. The decrease is due to the ~~lower utilization~~elimination of ~~medical services resulting from COVID-19.~~several of the COVID-19 risk corridors.

Medical Care Costs

We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the potential resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment experienced in the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 is likely the result of service deferrals, and so these services will likely be provided to members over the remainder of the year.

Capital and Financial Resources

OTHER RECENT DEVELOPMENTS

California Procurement—Medicaid. In April 2022, we submitted our RFP response. We expect the award to be announced in early August 2022, with an effective date of January 2024.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2724

Table of Contents

~~AFFORDABLE CARE ACT~~

Texas Procurement—Medicaid. In ~~December 2018, in a case brought by~~March 2022, the ~~state of~~ Texas Health and ~~nineteen other states, a federal judge~~Human Services Commission posted the ABD program (known in Texas held that the individual mandate of the ACA is unconstitutional. He further held that since the individual mandate is inseverable from the entire body of the ACA, the entire ACA is unconstitutional. The effect of his ruling was stayed pending the appeal of the rulingas STAR+PLUS) RFP, with awards estimated to the Fifth Circuit Court of Appeals. In December 2019, a three-judge panel of the Fifth Circuit Court of Appeal, in a two to one decision, affirmed the District Court’s ruling that the individual mandate is unconstitutional, but remanded the case back to the District Court for further consideration of the severability issue. The intervenor defendant states led by California subsequently appealed the case to the U.S. Supreme Court, which heard oral argumentsbe announced in the ~~case on November 10, 2020. In June 2021, the Supreme Court held~~fourth quarter of 2022, and start of operations in ~~a 7-2 opinion that the states~~September 2023.

Texas Acquisition—Medicaid and individuals that brought the lawsuit challenging the ACA’s individual mandate did not have standing to challenge the law. Although the Supreme Court did not reach the merits of the challenge, it vacated the District Court’s judgment and remanded the case with instructions to dismiss—effectively ending the case.

~~OTHER RECENT DEVELOPMENTS~~

~~New York Acquisition—Medicaid.~~Medicare. On ~~October 25, 2021,~~January 1, 2022, we closed on our acquisition of ~~substantially all of the assets of Affinity Health~~Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan ~~Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of~~(“MMP”) contracts, along with certain ~~tax benefits and allocation of required regulatory capital, which we funded with cash on hand.~~

~~California Procurement—Medicaid.~~Marketplace Enrollment. ~~The state currently expects a final RFP~~We now expect to ~~be released in February 2022.~~

~~Texas Acquisition—Medicaid~~end 2022 with approximately 270,000 members, reflecting normal attrition over the remainder of the year and ~~Medicare.~~ ~~On April 22, 2021, we announced a definitive agreement~~limited special enrollment period growth based on revised eligibility rules and our product design and distribution strategy. This represents an increase compared to ~~acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As~~our previous estimate of ~~December 31, 2020, Cigna served approximately 48,000~~250,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.

~~Ohio Procurement—Medicaid.~~ On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award issued on September 30, 2020, by the ~~Ohio Department~~end of ~~Medicaid. This new contract is expected to begin July 1,~~ 2022, resulting from stronger final enrollment and ~~will offer health care coverage to Medicaid beneficiaries through the state of Ohio’s Covered Family and Children, Expansion, and ABD programs.~~grace period membership.

For a discussion of additional segment trends, uncertainties and other developments, refer to our ~~2020~~2021 Annual Report on Form 10-K, “Item 1. Business—Our Business,” and “—Legislative and Political Environment.”

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 28~~

~~Table of Contents~~

REPORTABLE SEGMENTS

As of ~~September 30, 2021,~~March 31, 2022, we served approximately ~~4.8~~5.1 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.

In the first quarter of 2021, we realigned our reportable operating segments to reflect recent changes in our internal operating and reporting structure, which is now organized by government program. TheseWe currently have 4 reportable segments ~~consist~~consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other.

HOW WE ASSESS PERFORMANCE

We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.

Management’s discussion and analysis of the change in medical margin is discussed below under “Segment Financial Performance.” For more information, see Notes to Consolidated Financial Statements, Note 10, “Segments.”

SEGMENT MEMBERSHIP

The following table sets forth our membership by segment as of the dates indicated:

September 30, December 31, September 30,
2021 (1)
2020 2020
Medicaid 3,981,000 3,599,000 3,595,000
Medicare 138,000 115,000 113,000
Marketplace 719,000 318,000 325,000
Total 4,838,000 4,032,000 4,033,000

~~____________________~~

~~(1)Approximately 200,000 members, from the Magellan Complete Care acquisition that closed on December 31, 2020, are included in the totals as of September 30, 2021, but not in prior periods.~~


	March 31,	December 31,	March 31,
	2022	2021	2021
Medicaid	4,566,000	4,329,000	3,859,000
Medicare	148,000	142,000	126,000
Marketplace	371,000	728,000	620,000
Total	5,085,000	5,199,000	4,605,000

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 2925

Table of Contents

SEGMENT FINANCIAL PERFORMANCE

The following ~~tables summarize~~table summarizes premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):

Three Months Ended September 30,
2021 2020
Premium
Revenue Medical
Margin MCR Premium
Revenue Medical
Margin MCR
Medicaid $ 5,146 $ 532 89.6 % $ 3,754 $ 509 86.4 %
Medicare 875 151 82.8 632 91 85.6
Marketplace 779 68 91.3 382 70 81.6
Total $ 6,800 $ 751 88.9 % $ 4,768 $ 670 85.9 %


		Nine Months Ended September 30,																			Three Months Ended March 31,
		2021										2020									2022								2021
		Premium Revenue				Medical Margin		MCR				Premium Revenue		Medical Margin				MCR			Premium Revenue		Medical Margin		MCR				Premium Revenue			Medical Margin			MCR

Medicaid	Medicaid			$	15,020					$	1,687					88.8	%				$	10,415	$	1,427	86.3	%	Medicaid	$	5,980		$	710		88.1		%		$	4,840	$	604	87.5	%
Medicare	Medicare	2,488				329		86.8				1,896		333				82.4		Medicare	943		128		86.5				799			77			90.3
Marketplace	Marketplace	2,181				331		84.8				1,133		272				76.0		Marketplace	608		130		78.6				667			151			77.3
Total	Total	$	19,689			$	2,347	88.1	%			$	13,444	$	2,032			84.9	%	Total	$	7,531	$	968	87.1	%			$	6,306		$	832		86.8		%

Medicaid

Medicaid premium revenue increased ~~$1,392 million~~$1.1 billion, or 24%, in the ~~third~~first quarter of ~~2021,~~2022, when compared with the ~~third~~first quarter of ~~2020. Medicaid premium revenue increased $4,605 million in the nine months ended September 30, 2021, when compared with the nine months ended September 30, 2020.~~2021. The increase ~~in both periods~~ was mainly due to organic membership growth, including Nevada, and the impact from the ~~Magellan Complete Care~~Affinity and ~~other~~Cigna acquisitions that closed in the ~~second half~~fourth quarter of ~~2020.~~2021 and in January 2022, respectively. Excluding the acquisitions, ~~the~~ membership growth was across several states and was mainly driven by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19. The ~~overall~~ increase was partially ~~offset by the~~attributable to a reduced impact of state risk corridors stemming from COVID-19.

As described above in “Trends and Uncertainties,” we recognized approximately ~~$17 million and $183~~$28 million in the ~~third~~first quarter ~~and nine months ended September 30, 2021, respectively,~~of 2022, for the impact of risk corridors enacted in several states beginning in the second quarter of 2020, in response to the lower utilization of medical services resulting from COVID-19. We recognized approximately $110 million for the impact of such risk corridors in the first quarter of 2021. The decrease is due to the elimination of most of the COVID-19 risk corridors.

The medical margin in our Medicaid program increased ~~$23~~$106 million, or 18%, in the ~~third~~first quarter of ~~2021~~2022 when compared with the ~~third~~first quarter of 2020. The increase in margin was driven by increased premium revenues, partially offset by the MCR increase discussed below. The medical margin in our Medicaid program increased $260 million in the nine months ended September 30, 2021 when compared with the nine months ended September 30, 2020.2021. The increase was driven by increased premium revenues and margin associated with the membership growth discussed above, partially offset by an increase in the ~~MCR increase discussed below.~~MCR.

The Medicaid MCR increased to ~~89.6%~~88.1% in the ~~third~~first quarter of 2022, from 87.5% in the first quarter of 2021, ~~from 86.4% in the third quarter of 2020, and increased to 88.8% in the nine months ended September 30, 2021, from 86.3% in the nine months ended September 30, 2020.~~or 60 basis points. The increase ~~for both periods is~~was mainly ~~driven by~~attributable to a year-over-year increase in the net effect of COVID, ~~and changes~~partially offset by improved operations, including medical cost management. The year-over-year change in ~~business mix. The~~the net effect of COVID ~~increased the MCR for the current year and~~ reflects an increase in COVID-related inpatient costs, and lower COVID-related utilization curtailment, ~~and~~partially offset by the ~~impact of the~~decrease in COVID-related risk ~~corridors enacted in several states as previously disclosed. In the prior year~~corridors. The Medicaid MCR is consistent with our long-term target despite the net effect of ~~COVID decreased the MCR.~~COVID.

Medicare

Medicare premium revenue increased ~~$243~~$144 million, or 18%, in the ~~third~~first quarter of ~~2021 compared to the third quarter of 2020 and increased $592 million in the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was~~2022, primarily due to the impact of product expansion and organic membership growth in existing states, partially offset by lower premium revenue PMPM from the ~~Magellan Complete Care acquisition,~~change in business mix.

The medical margin for Medicare increased $51 million, in the first quarter of 2022, when compared with the first quarter of 2021, mainly due to the increase in premium revenues and the improvement in the MCR discussed below.

The Medicare MCR decreased to 86.5% in the first quarter of 2022, from 90.3% in the first quarter of 2021, or 380 basis points. The improvement was primarily driven by a lower net effect of COVID, improved operating performance, including higher risk scores that more closely reflect the acuity of our membership, and ~~higher~~the change in business mix. The Medicare MCR is lower than our long-term target.

Marketplace

Marketplace premium revenue in the first quarter of 2022 decreased $59 million, compared with the first quarter of 2021, mainly due to a reduction in membership, partially offset by an increase in premium revenue PMPM. Our Marketplace membership as of March 31, 2022 amounted to 371,000 members, representing a decline of 357,000 members compared to December 31, 2021, which is in line with our product and pricing strategy to achieve our target margins in this business. The increase in premium revenue PMPM is consistent with the product and pricing

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3026

Table of Contents

~~The medical margin for Medicare increased $60 million~~strategy, reflectingan increase of members in the ~~third quarter of 2021~~silver metal tier and decreased $4 million in the nine months ended September 30, 2021, when compared to the same periods in 2020. The year-over-year changes in margin are driven by an increase in premium revenue and changes in the MCR.

The Medicare MCR decreased to 82.8% in the third quarter of 2021, from 85.6% in the third quarter of 2020, mainly due to a favorable impact from the net effect of COVID, including utilization curtailment and corridor related adjustments. The Medicare MCR increased to 86.8% in the nine months ended September 30, 2021, compared to 82.4% in the nine months ended September 30, 2020, primarily driven by the net effect of COVID, including higher direct COVID medical costs, and the temporary industry-wide challenge of risk scores that do not fully reflect the acuity of our membership. COVID-related utilization curtailment drove a lower MCR for the nine months ended September 30, 2020.

~~Marketplace~~

Marketplace premium revenue increased $397 million in the third quarter of 2021 compared to the third quarter of 2020 and increased $1,048 million in the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020. The increase was mainly due to higher membership, partially offset by a decrease in premium revenue PMPM. Our Marketplace membership as of September 30, 2021, amounted to 719,000 members, representing growth of 81,000 members sequentially compared to June 30, 2021, and substantially exceeding our expectations. This improvement resulted from several factors, including strong product design and competitive pricing, better than expected natural attrition rates, and the extended open enrollment period. The decrease in premium revenue PMPM was mainly driven by changes in business mix, with an increase of members in the bronze metal tier.

The Marketplace medical margin decreased $2$21 million in the ~~third~~first quarter of ~~2021~~2022, when compared with the ~~third~~first quarter of ~~2020,~~2021, primarily due to the decrease in membership and premiums, and the increase in the MCR partially offset by the impact of increased premium revenue. The Marketplace medical margin increased $59 million in the nine months ended September 30, 2021 when compared with the nine months ended September 30, 2020, primarily due to the increase in membership and premiums, mostly offset by an increase in the MCR compared to 2020.described below.

The Marketplace MCR increased to ~~91.3%~~78.6% in the ~~third~~first quarter of 2022, from 77.3% in the first quarter of 2021, ~~compared to 81.6% in the third quarter of 2020, and increased to 84.8% in the nine months ended September 30, 2021, compared to 76.0% in the nine months ended September 30, 2020.~~or 130 basis points. The increase ~~for both periods~~ resulted mainly from ~~higher direct COVID medical costs,~~changes in membership mix discussed above. Silver metal tier products incur less MCR seasonality than bronze metal tier products due to ~~continued COVID utilization pressure~~lower deductibles. The Marketplace MCR is in ~~many of~~line within our ~~Marketplace geographies, and non-COVID utilization by members enrolled through the special enrollment period.~~long-term target.

Other

The Other segment includes service revenues and costs associated with ~~the~~ long-term services and supports consultative services we ~~now~~ provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations ~~for~~in the ~~third quarter~~first quarters of 2022 and ~~nine months ended September 30,~~ 2021, ~~and 2020.~~respectively.

LIQUIDITY AND FINANCIAL CONDITION

LIQUIDITY

We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.

We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity. In the first ~~half~~quarter of ~~2021,~~2022, we did not experience noticeable delays to, or changes in, the timing or level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below in “Future Sources and Uses of Liquidity—Future Uses—Potential Impact of COVID-19 Pandemic.”

A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 31~~

~~Table of Contents~~

general corporate purposes. In the ~~third quarter and nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the parent company received ~~$127~~$115 million, ~~and $346 million, respectively,~~ in dividends and return of capital from the regulated health plan subsidiaries. See further discussion of dividends below in “Future Sources and Uses of Liquidity—Future Sources.”

The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans. In the ~~third quarter and nine~~three months ended ~~September 30, 2021,~~March 31, 2022, the parent company contributed capital of ~~$23 million and $110~~$19 million, ~~respectively,~~ to the regulated health plan subsidiaries.

Cash, cash equivalents and investments at the parent company amounted to ~~$703~~$250 million and ~~$644~~$348 million as of ~~September 30, 2021,~~March 31, 2022, and December 31, ~~2020,~~2021, respectively. The ~~increase~~decrease as of ~~September 30, 2021,~~March 31, 2022, was ~~mainly~~primarily due to the ~~dividends received from the regulated health plan subsidiaries in the nine months ended September 30, 2021, partially offset by the~~timing of corporate payments and capital ~~contributed~~contributions to regulated health plan subsidiaries, and our share repurchase program. In the first quarter of 2021, we purchased an aggregate of approximately 577,000 shares for $122 million, and we also paid $6 million to settle shares purchased in late December 2020.partially offset by dividends received from regulated health plan subsidiaries.

Investments

After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations.

Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 1015 years, or less than 1015 years average life for structured securities. Professional portfolio managers operating under

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 27

Table of Contents

documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels.

We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated AA. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets.

Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets.

Cash Flow Activities

Our cash flows are summarized as follows:

Nine Months Ended September 30,
2021 2020 Change
(In millions)
Net cash provided by operating activities $ 1,522 $ 599 $ 923
Net cash (used in) provided by investing activities (1,106) 98 (1,204)
Net cash (used in) provided by financing activities (204) 61 (265)
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents $ 212 $ 758 $ (546)


	Three Months Ended March 31,
	2022		2021		Change

	(In millions)
Net cash provided by operating activities	$	363	$	568	$	(205)
Net cash provided by (used in) investing activities	74		(87)		161
Net cash used in financing activities	(77)		(207)		130
Net increase in cash, cash equivalents, and restricted cash and cash equivalents	$	360	$	274	$	86

Operating Activities

We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month’s premium payment.

Net cash provided by operations for the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 was ~~$1,522~~$363 million, compared with ~~$599~~$568 million in the ~~nine~~three months ended ~~September 30, 2020.~~March 31, 2021. The ~~$923~~$205 million ~~increase~~decrease in cash flow was due to ~~the growth in operations and~~ the net impact of timing differences in government receivables and ~~payables.~~

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 32~~

~~Table of Contents~~

payables and partially offset by an increase in net earnings.

Investing Activities

Net cash provided by investing activities was $74 million in the three months ended March 31, 2022, compared with $87 million used in investing activities ~~was $1,106 million~~ in the ~~nine~~three months ended ~~September 30,~~March 31, 2021, ~~compared with $98 million provided by investing activities in the nine months ended September 30, 2020, a decrease~~an increase in cash flow of ~~$1,204~~$161 million. This ~~decrease~~increase in cash flow was primarily due to ~~increased~~the net activity of proceeds and purchases of investments in the ~~nine~~three months ended ~~September 30, 2021.~~March 31, 2022.

Financing Activities

Net cash used in financing activities was ~~$204~~$77 million in the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, compared with ~~$61~~$207 million ~~provided by financing activities~~used in the ~~nine~~three months ended ~~September 30, 2020, a decrease~~March 31, 2021, an increase in cash flow of ~~$265~~$130 million. In the ~~nine~~three months ended ~~September 30,~~March 31, 2022, cash outflow included $52 million for common stock withheld to settle employee tax obligations. In the three months ended March 31, 2021, financing cash outflows included common stock purchases of $128 million and ~~$52~~$51 million for common stock withheld to settle employee tax obligations. Additionally, we paid ~~$23~~$20 million each in the first quarters of 2022 and 2021 to settle contingent consideration liabilities relating to our Kentucky Passport acquisition that closed in 2020, $20 million of which has been presented as a financing cash outflow. In the nine months ended September 30, 2020, financing cash inflows included $380 million borrowed under the term loan facility and net proceeds of $189 million related to the repayment of the term loan facility and issuance of senior notes. This was offset by financing cash outflows related to common stock purchases of $453 million, common stock withheld to settle employee tax obligations of $8 million, and other financing outflows of $47 million.2020.

FINANCIAL CONDITION

We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in “Future Sources and Uses of Liquidity—Future Sources,” and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months.

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 28

Table of Contents

On a consolidated basis, at ~~September 30, 2021,~~March 31, 2022, our working capital was ~~$3.3~~$3.1 billion, compared with ~~$2.9~~$3.0 billion at December 31, ~~2020.~~2021. At ~~September 30, 2021,~~March 31, 2022, our cash and investments amounted to ~~$7.4~~$8.0 billion, compared with ~~$6.2~~$7.9 billion at December 31, ~~2020.~~2021.

Regulatory Capital and Dividend Restrictions

Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately ~~$1.9~~$2.1 billion at ~~September 30, 2021, compared with $1.5 billion at~~both March 31, 2022 and December 31, ~~2020.~~2021. The aggregate capital and surplus of our wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates.

Under applicable regulatory requirements, the amount of dividends that may be paid by our wholly owned subsidiaries without prior approval by regulatory authorities as of ~~September 30, 2021,~~March 31, 2022, was approximately ~~$182~~$229 million in the aggregate. The subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.

Based on our cash and investments balances as of ~~September 30, 2021,~~March 31, 2022, management believes that our regulated, wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.

Debt Ratings

Each of our ~~high-yield~~ senior notes is rated “BB-” by Standard & Poor’s, and “Ba3” by Moody’s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our future borrowing costs.

Financial Covenants

The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement.

In addition, the indentures governing each of our outstanding ~~high-yield~~ senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of ~~September 30, 2021,~~March 31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 33~~

~~Table of Contents~~

FUTURE SOURCES AND USES OF LIQUIDITY

Future Sources

Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.

Potential Impact of COVID-19 Pandemic. Excluding acquisitions and our exit from Puerto Rico, we ~~have~~ added over ~~700,000~~750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. We expect Medicaid enrollment to continue to benefit from the extension of the PHE period, and the associated pause on membership redeterminations, at least through ~~mid-January~~mid-July 2022.

Dividends from Subsidiaries. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could further restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.

Credit Agreement Borrowing Capacity. As of ~~September 30, 2021,~~March 31, 2022, we had available borrowing capacity of $1 billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15 million swingline sub-facility and a $100 million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500 million, plus an unlimited amount of such term loans as long as

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 29

Table of Contents

our consolidated net leverage ratio is not greater than a defined maximum. See further discussion in the Notes to Consolidated Financial Statements, Note 8, “Debt.”

Future Uses

Common Stock Purchases. In September 2021, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This new program, ~~immediately supersedes~~which superseded the stock purchase program ~~previously~~ approved by our board of directors in September ~~2020. This new program will be~~2020, is funded with cash on hand and extends through December 31, 2022. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of ~~October 28, 2021, $500~~April 27, 2022, $472 million remained available to purchase our common stock under this program through December 31, 2022.

Acquisitions. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York. The net purchase price for the transaction is approximately $380 million, net of certain tax benefits and allocation of required regulatory capital, which we funded with cash on hand.

On October 7, 2021, we announced a definitive agreement to acquire the Medicaid Managed Long Term Care business of AgeWell New York. ~~As of August 31, 2021, AgeWell served approximately 13,000 managed long-term services and supports members, with full-year 2020 premium revenue of approximately $700 million.~~ The purchase price for the transaction is approximately ~~$110~~$106 million, net of certain tax benefits and target allocation of required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close by the third quarter of 2022.

On April 22, 2021, we announced a definitive agreement to acquire Cigna Corporation’s Texas Medicaid and Medicare-Medicaid Plan (“MMP”) contracts, along with certain operating assets. As of December 31, 2020, Cigna served approximately 48,000 members in the Texas ABD program, also known as “STAR+PLUS,” in the Hidalgo, Tarrant and Northeast service areas, and approximately 2,000 MMP members in the Hidalgo service area, with full year 2020 premium revenue of approximately $1.0 billion. The purchase price for the transaction is approximately $60 million, which we intend to fund with cash on hand. The transaction is subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of other customary closing conditions. We currently expect the transaction to close in January 2022.

Potential Impact of COVID-19 Pandemic. As described above in “Trends and Uncertainties,” we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, ~~through September 30, 2021,~~ various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from ~~COVID-19,~~COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 34~~

~~Table of Contents~~

retroactive to earlier periods in 2020, or as early as the beginning of the states’ fiscal years in 2019. Beginning in the second quarter of 2020, we have recognized ~~retroactive~~ risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, we recognized approximately ~~$17~~$28 million ~~and $183 million, respectively,~~ related to such risk corridors, primarily in the Medicaid segment.

Regulatory Capital ~~Requirements and Dividend Restrictions.~~Requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.

CONTRACTUAL OBLIGATIONS

A summary of future obligations under our various contractual obligations and commitments as of December 31, ~~2020,~~2021, was disclosed in our ~~2020~~2021 Annual Report on Form 10-K.

There were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the ~~nine~~three months ended ~~September 30, 2021.~~March 31, 2022.

CRITICAL ACCOUNTING ESTIMATES

When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:

•Medical claims and benefits payable. Refer to Notes to Consolidated Financial Statements, Note 7, “Medical Claims and Benefits Payable,” for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, in the ~~nine~~three months ended ~~September 30, 2021~~March 31, 2022 there ~~have been~~were no significant changes to our disclosure reported in “Critical Accounting Estimates” in our ~~2020~~2021 Annual Report on Form 10-K.

•Contractual provisions that may adjust or limit revenue or profit. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”

Molina Healthcare, Inc. March 31, 2022 Form 10-Q | 30

Table of Contents

•Quality incentives. In the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, there ~~have been~~were no significant changes to our disclosure reported in “Critical Accounting Estimates” in our ~~2020~~2021 Annual Report on Form 10-K.

•Business combinations, goodwill, and intangible assets, net. In the ~~first quarter of 2021, we realigned~~three months ended March 31, 2022, there were no significant changes to our ~~reportable operating segments to reflect recent changes~~disclosure reported in “Critical Accounting Estimates” in our internal operating and reporting structure, which is now organized by government program. The revised reporting structure reflects the reporting and review process used by our chief executive officer (who is our chief operating decision maker) to assess performance and allocate resources, and is consistent with how we currently manage the business and view the markets we serve. These reportable segments consist of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. Such reportable operating segments also now constitute our reporting units in the annual assessment of goodwill impairment. Refer to Notes to Consolidated Financial Statements, Note 10, “Segments,” for a presentation of goodwill, and intangibles assets, net, by reportable segment, and “Critical Accounting Estimates,” in our 20202021 Annual Report on Form ~~10-K, for further information.~~10-K.

~~Molina Healthcare, Inc. September 30, 2021 Form 10-Q | 35~~

~~Table of Contents~~

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.

Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at ~~September 30, 2021,~~March 31, 2022, the fair value of our fixed income investments would decrease by approximately ~~$67~~$69 million. Declines in interest rates over time will reduce our investment income.

For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, “Fair Value Measurements,” and Note 6, “Investments.”

Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, “Debt.”

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control Over Financial Reporting. There ~~has been~~were no ~~change~~changes in our internal control over financial reporting during the ~~nine~~three months ended ~~September 30, 2021,~~March 31, 2022, that ~~has~~ materially affected, or isare reasonably likely to materially affect, our internal controls over financial reporting.

LEGAL PROCEEDINGS

For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, “Commitments and Contingencies.”

RISK FACTORS

Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed under the caption “Risk Factors,” in our ~~2020~~2021 Annual Report on Form 10-K. The risk factors described in our ~~2020~~2021 Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3631

Table of Contents

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ISSUER PURCHASES OF EQUITY SECURITIES

Purchases of common stock made by us, or on our behalf, during the ~~third~~first quarter of ~~2021,~~2022, including shares withheld by us to satisfy our employees’ income tax obligations, are set forth below:

Total Number
of Shares
Purchased (1)
Average Price Paid per Share Total Number of Shares
Purchased as Part of
Publicly
Announced
Plans or
Programs
Approximate Dollar Value
of Shares that May Yet Be Purchased Under the Plans or Programs (2)
July 1 - July 31 2,000 $ 256.05 — $ 219,000,000
August 1 - August 31 — $ — — $ 219,000,000
September 1 - September 30 — $ — — $ 500,000,000
Total 2,000 $ 256.05 —


	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)
January 1 - January 31	1,000	$	291.89	—	$	500,000,000
February 1 - February 28	—	$	—	—	$	500,000,000
March 1 - March 31	165,000	$	311.88	—	$	500,000,000
Total	166,000	$	311.71	—

_______________________

(1)During the ~~third~~first quarter of ~~2021,~~2022, we withheld approximately ~~2,000~~166,000 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan.

(2)For further information on our stock repurchase programs, refer to Note 9, “Stockholders' Equity.”

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3732

Table of Contents

INDEX TO EXHIBITS

Exhibit No.

Title

Method of Filing

10.1

~~Amended and Restated~~Amendment of Employment Agreement, ~~effective as of September 8, 2021,~~date d February 16, 2022, by and between Jos eph M. Zubretsky and Molina Healthcare, Inc. ~~and Joseph M. Zubretsky.~~

Filed as Exhibit 10.1 to registrant’s Form 8-K filed ~~September 9, 2021.~~February 16, 2022.

31.1

Section 302 Certification of Chief Executive Officer

Filed herewith.

31.2

Section 302 Certification of Chief Financial Officer

Filed herewith.

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Filed herewith.

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Filed herewith.

101.INS

Inline XBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.

Filed herewith.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

Filed herewith.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

Filed herewith.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

Filed herewith.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

Filed herewith.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

104

Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)

Filed herewith.

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3833

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		MOLINA HEALTHCARE, INC.
		(Registrant)

Dated:	~~October~~April 28, ~~2021~~2022	/s/ JOSEPH M. ZUBRETSKY
		Joseph M. Zubretsky
		Chief Executive Officer
		(Principal Executive Officer)

Dated:	~~October~~April 28, ~~2021~~2022	/s/ MARK L. KEIM
		Mark L. Keim
		Chief Financial Officer and Treasurer
		(Principal Financial Officer)

Molina Healthcare, Inc. ~~September 30, 2021~~March 31, 2022 Form 10-Q | 3934


	Nine Months Ended September 30, 2020
	Medicaid		Medicare		Marketplace		Consolidated

	(In millions)
Medical claims and benefits payable, beginning balance	$	1,465	$	267	$	122	$	1,854
Components of medical care costs related to:
Current year	9,029		1,588		861		11,478
Prior years	(41)		(25)		—		(66)
Total medical care costs	8,988		1,563		861		11,412
Payments for medical care costs related to:
Current year	7,470		1,316		714		9,500
Prior years	1,193		233		101		1,527
Total paid	8,663		1,549		815		11,027
Change in non-risk and other provider payables	50		—		—		50
Medical claims and benefits payable, ending balance	$	1,840	$	281	$	168	$	2,289